Key Highlights

  • High Tide reported record third quarter Revenue of 198.8 million Canadian dollars, up 33 percent year over year, the fastest growth pace in 13 quarters.
  • Adjusted EBITDA reached a record 16.2 million Canadian dollars, up 52 percent year over year, with consolidated adjusted EBITDA Margin hitting a 12-quarter high of 8.2 percent.
  • The company's German medical cannabis distribution subsidiary, Remexian, sold 10.2 tons of cannabis during the quarter, up 35 percent sequentially and 165 percent above the pace at acquisition.
  • Same-store sales in Canada were roughly flat for the quarter, with transaction counts up 1.1 percent even as macroeconomic pressures compressed average basket size.

Record results across bricks-and-mortar and distribution segments

High Tide Inc. (NASDAQ:HITI), a Calgary-based cannabis retailer operating Canada's largest cannabis retail chain alongside its German medical cannabis distribution Business Remexian, reported third quarter fiscal 2026 revenue of 198.8 Canadian dollars million, an increase of 33 percent year over year representing the fastest growth rate in 13 quarters. Gross Profit reached a record 52.7 million Canadian dollars, up 32 percent year over year, with both the company's bricks-and-mortar and medical cannabis distribution segments posting new records.

Adjusted EBITDA of 16.2 million Canadian dollars increased 52 percent year over year, while income from operations reached a record 8.7 million Canadian dollars, up 133 percent, exceeding the combined Operating Income generated during the first two quarters of the fiscal year. Net Income reached a record 12.7 million Canadian dollars, though adjusted net income of 2.2 million Canadian dollars, which excludes a favorable Fair Value change in derivative liability, better reflects underlying operating performance and was up 186 percent sequentially and 157 percent year over year.

Loyalty-driven Canadian retail alongside accelerating German distribution

In Canada, the company's Canna Cabana retail chain continued to outperform the broader industry, supported by its Cabana Club loyalty program, which reached 2.73 million members, up 27 percent year over year, alongside a paid ELITE membership tier that grew 62 percent to exceed 186,000 members. Management reported that same-store sales were roughly consistent with the prior year for the quarter, with transaction counts up 1.1 percent even as customers shifted toward thinner baskets amid macroeconomic pressure, a trend the company said reflects continued customer loyalty rather than customer attrition.

In Germany, Remexian sold 10.2 tons of medical cannabis during the quarter, an increase of 35 percent sequentially and 165 percent above the pace the business was operating at when the Acquisition closed roughly a year earlier. Remexian revenue of 38.2 million Canadian dollars grew 21 percent sequentially, while adjusted EBITDA grew nearly twice as fast at 38 percent to a record 4.4 million Canadian dollars, representing a 12 percent adjusted EBITDA margin, aided by the company's ability to procure Canadian cannabis at favorable terms for export to the rapidly growing German market.

Balancing continued expansion against a maturing competitive landscape

If German medical cannabis Import volumes continue their current trajectory, which management noted reached an annualized run rate of approximately 517 million Canadian dollars industry-wide, up 62 percent year over year, Remexian's tonnage growth could continue even if the pace of Market Share gains moderates given how quickly the addressable market itself has expanded. Management indicated it continues to see room to grow both store count in Canada, with 118 planned locations remaining to reach its 350-store target, and Volume in Germany without near-term capacity constraints.

At the same time, the Canadian cannabis retail market faces its own competitive dynamics, including a 5 percent increase in store count across Ontario and Alberta over the past 12 months and consumers exhibiting more cautious spending behavior amid Inflation and economic uncertainty. Management also acknowledged that Germany's routine annual import Quota adjustments, which occur every year including a period of short-term Supply constraints, could create temporary disruption before quotas are typically increased within four to six weeks, a pattern the company expects to repeat but does not view as a structural risk to its Long-term Growth trajectory.

A dual-market growth story built on loyalty and procurement scale

High Tide's third quarter results reflect a business simultaneously defending its Leadership position in a maturing Canadian cannabis retail market while capturing outsized share of a rapidly expanding German medical cannabis import market. The combination of loyalty-driven customer retention in Canada and procurement-driven margin expansion in Germany produced records across nearly every reported financial metric. Whether the company can sustain this dual growth trajectory as both markets evolve, particularly as German import volumes scale and Canadian same-store sales trends stabilize, will shape its performance through the remainder of the fiscal year.